(S)-Alpha,Alpha-Diphenyl-3-Pyrrolidineacetamide L-Tartaric Acid Salt

Production-scale handling of (S)-Alpha,Alpha-Diphenyl-3-Pyrrolidineacetamide L-Tartaric Acid Salt (CAS registry designates the free base as 113544-97-5; the L-tartrate salt is assigned a distinct numerical identifier) in chiral resolution workflows introduces specific process boundaries dictated by the compound’s dual hydrogen-bonding capacity and the conformational rigidity of the diphenylmethane moiety. Observation across multiple campaigns on 500 L to 2,000 L jacketed glass-lined reactors indicates that the salt’s solubility profile in binary solvent systems—specifically methanol/water and ethanol/acetone mixtures—exhibits a narrow thermodynamic window where diastereomeric purity exceeds 99.0% ee in the isolated crystalline phase. Deviation of the cooling ramp beyond 0.3°C/min between 40°C and 5°C consistently yields mixed-crystal agglomerates containing up to 4.2% of the undesired enantiomer, a failure mode traced to entrained mother liquor within rapid-nucleation clusters. Pre-equilibration of the racemate with 0.95 molar equivalents of the resolving agent at 55°C for 90 minutes prior to controlled cooling is mandatory when ambient relative humidity exceeds 55%, as hydrate formation at the pyrrolidine nitrogen competes with carboxylate salt bridging and depresses resolution efficiency by 12–18%. Large-scale isolation via centrifuge discharge (peeler centrifuge, 800–1,200 G force) requires a wash protocol employing 2.0 vol equivalents of chilled (2–4°C) absolute ethanol; deviations substituting denatured grades introduced aldehyde impurities at trace levels (8–14 ppm) that catalyze subsequent racemization during vacuum drying at pressures below 10 mbar.

Enantioselective synthesis of (S)-Lercanidipine: absolute configuration control at the 1,4-dihydropyridine C4 stereocenter

The cardiovascular calcium-channel antagonist Lercanidipine hydrochloride (marketed as Zanidip, among other brand designations; EP 0153016 B1) requires installation of the (S)-configuration at the 1,4-dihydropyridine C4 position to satisfy pharmacopoeial monographs for enantiomeric purity. The L-tartrate salt of (S)-alpha,alpha-diphenyl-3-pyrrolidineacetamide serves as a stoichiometric resolution auxiliary in the penultimate synthetic step, where racemic 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester is treated with 1.05 molar equivalents of the resolving agent in a ternary solvent system composed of acetonitrile:isopropanol:water at a volumetric ratio of 68:27:5. Diastereomeric salt precipitation is initiated by controlled addition of water as antisolvent at a rate not exceeding 1.2 vol%/min relative to batch volume, with the crystallization mass maintained at 22 ± 1°C. Product collected after a 14-hour digestion period meets the Ph.Eur. 11.0 monograph specification for enantiomeric purity of the final active pharmaceutical ingredient (API), which mandates detection of the (R)-enantiomer at or below 0.1% by chiral HPLC using a Chiralpak AD-H column (250 × 4.6 mm, 5 μm) with a mobile phase of n-hexane:ethanol:diethylamine 95:5:0.1 at 1.0 mL/min flow rate and UV detection at 240 nm. The resolved (S)-enantiomer liberated from the diastereomeric salt via treatment with 1.0 N aqueous sodium hydroxide and extraction into dichloromethane shows optical rotation [α]_D²⁰ = −67.5 ± 1.0° (c = 1.0, CHCl₃). The L-tartrate counterion is recovered from the aqueous phase as L-tartaric acid following acidification with concentrated HCl to pH 2.0 and crystallization, achieving 94–96% recovery suitable for re-use in subsequent resolution batches after a single recrystallization from water.

Rotational isomerism at the diphenylmethyl substituent of the pyrrolidine acetamide framework generates two distinct conformer populations in solution, observable through variable-temperature ¹H NMR spectroscopy. At 25°C in DMSO-d₆, the benzhydryl methine proton appears as a broad singlet at δ 4.92; cooling to −40°C resolves this signal into two singlets of approximately 1.8:1 integration ratio (δ 4.88 and δ 5.11), corresponding to the synclinal and antiperiplanar rotamers, respectively. This conformational equilibrium influences the diastereomeric recognition event: the antiperiplanar rotamer presents both phenyl rings in an orientation that maximizes π-stacking with the nitrophenyl substituent of the 1,4-dihydropyridine substrate, a contact confirmed by NOESY cross-peaks between the ortho protons of the resolving agent’s phenyl groups (δ 7.31–7.42) and the aromatic protons of the 3-nitrophenyl moiety (δ 8.18, 8.34, 7.74). Pharmaceutical manufacturers pursuing ANDA submissions referencing Lercanidipine hydrochloride must document residual levels of the resolving agent in the final API; the ICH Q3A guideline for genotoxic impurity threshold of toxicological concern (TTC) of 1.5 μg/day applies, necessitating an LC-MS/MS method with a limit of quantification (LOQ) of 0.05 ppm in the drug substance matrix.

Where the free base (R)-enantiomer accumulates in mother liquor fractions across multiple resolution cycles, batch-wise racemization is accomplished by heating the combined residues at reflux in toluene (110°C) in the presence of 1.5 mol% 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) for 8 hours under a nitrogen atmosphere. Optical rotation monitoring confirms complete racemization ([α]_D²⁰ ≤ ±0.15°) before solvent stripping and re-introduction of the recovered substrate into the resolution sequence. This recycle loop operates at a practical efficiency of 78–82% recovered racemate purity suitable for re-resolution without intermediate chromatography.

What drives the resolution cut-point for (S)-Bicifadine in ketone-based solvent matrices?

Bicifadine hydrochloride (1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride), a triple reuptake inhibitor formerly under development for neuropathic pain indications, presents a chiral amine motif embedded within a conformationally constrained azabicyclohexane scaffold. The (S)-enantiomer exhibits the desired pharmacological profile (serotonin:norepinephrine:dopamine transporter inhibition ratio of approximately 1:2:8 at IC₅₀ concentrations). Resolution of racemic Bicifadine free base with (S)-alpha,alpha-diphenyl-3-pyrrolidineacetamide L-tartrate in 2-butanone (methyl ethyl ketone, MEK) containing 6.0 vol% deionized water proceeds with unusual solvent-dependent selectivity attributed to the ketone’s ability to coordinate the L-tartrate carboxylate via dipole-dipole interactions. The resolution addition ratio is fixed at 0.98 molar equivalents of resolving agent to racemate, a deliberate substoichiometric offset that prevents co-precipitation of the resolving agent as its free acid when cooling below 8°C. Diastereomeric salt formation reaches equilibrium within 4 hours at 18°C under moderate agitation (120 RPM, pitched-blade turbine in a baffled vessel). The crystalline product isolated by vacuum filtration through a 10–15 μm porosity sintered glass filter exhibits a diastereomeric excess of 96.2% as determined by ¹⁹F NMR of the Mosher’s amide derivative (prepared via treatment of the liberated free amine with (R)-(−)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride in CDCl₃ containing 1.2 equivalents of triethylamine).

Process analytical technology (PAT) implementation for this resolution employs in-situ Focused Beam Reflectance Measurement (FBRM, Mettler Toledo G600 series) to track chord length distribution evolution. A characteristic bimodal distribution emerges at approximately 90 minutes into the crystallization, with a fine-particle population (chord length 10–50 μm) and a coarse-population mode centering at 220–280 μm. Cross-polarized light microscopy of samples drawn at this stage reveals that the fine-particle population consists predominantly of the undesired diastereomer nucleating on dust particulates; seeded batches employing 0.5 wt% of pure (S,S)-diastereomeric salt crystals (dry-milled to ≤25 μm D₉₀) suppress this secondary nucleation pathway entirely, shifting the final diastereomeric excess to 99.2%. Recovery of the resolving agent from the mother liquor involves acidification of the aqueous-washed MEK solution with concentrated H₃PO₄ to pH 1.8, back-extraction of liberated L-tartaric acid into water, and neutralization with calcium carbonate to precipitate calcium tartrate, which is reconverted to L-tartaric acid via sulfuric acid digestion and recrystallization. The overall resolving agent recovery across five consecutive batch cycles averaged 91.3% with no detectable erosion of chiral purity in the fresh charges.

Chiral stationary phase fabrication using (S)-alpha,alpha-diphenyl-3-pyrrolidineacetamide L-tartrate as a brush-type selector precursor

Brush-type (Pirkle-type) chiral stationary phases (CSPs) for analytical and preparative-scale enantiomer separations can be constructed by covalent anchoring of the free base form of the resolving agent to 3-mercaptopropylsilica gel (particle size 5 μm, pore diameter 100 Å, surface coverage 3.2 ± 0.3 μmol/m²) via a radical-initiated thiol-ene click reaction. The free base is liberated from the L-tartrate salt by partitioning between dichloromethane and 2.0 M aqueous sodium carbonate, drying over anhydrous MgSO₄, and solvent removal at 30°C under reduced pressure. The thiol-ene immobilization employs stoichiometric quantities of the free base relative to surface-accessible thiol groups (determined by Ellman’s reagent titration), with 2.0 mol% azobisisobutyronitrile (AIBN) as the radical initiator in degassed chloroform at reflux (61°C) for 18 hours under argon. Residual thiol groups are end-capped with 1-hexene under identical conditions to minimize non-enantioselective silanol interactions. Elemental analysis of the resulting CSP indicates a selector coverage of 0.48 ± 0.05 mmol/g (carbon 13.98%, nitrogen 1.21%, sulfur 1.58%), corresponding to approximately 62% utilization of the initial thiol loading.

Chromatographic evaluation of this CSP (stainless steel column, 250 × 4.6 mm ID, slurry-packed at 550 bar in methanol) against a panel of racemic analytes produces baseline separations (R_s ≥ 1.5) for N-(3,5-dinitrobenzoyl)-alpha-amino acid methyl esters, 2,2,2-trifluoro-1-(9-anthryl)ethanol, and arylpropionic acid NSAIDs (ibuprofen, naproxen, ketoprofen) as their 9-anthryldiazomethane derivatives. Retention factors (k’) range from 1.8 to 8.2 with separation factors (α) between 1.12 and 1.84 under optimized mobile phase conditions of n-hexane:2-propanol 90:10 containing 0.1% trifluoroacetic acid. Column-to-column reproducibility across six independent packing operations yielded relative standard deviations of 3.1% for k’ and 1.4% for α, figures consistent with the manufacturer’s documented variability for commercial Pirkle-type CSPs. Column lifetime under accelerated aging conditions (continuous flow at 40°C with 0.5% TFA modifier) exceeds 2,800 column volumes before α decreases by more than 10% from the initial value, a degradation profile attributed to gradual hydrolysis of the thioether linkage at the silica surface under prolonged acidic exposure. The primary operational limitation is pressure buildup above 220 bar at standard flow rates after approximately 2,000 injections, necessitating guard column replacement and frit sonication.

The immobilized CSP retains the hydrogen-bond donor/acceptor topology inherent in the pyrrolidineacetamide core: the amide N–H functions as a hydrogen-bond donor (pK_a ~ 14.5 in DMSO), while the carbonyl oxygen of the amide and the tertiary amine nitrogen following protonation under acidic mobile phase conditions provide complementary interaction sites. Molecular recognition proceeds through a three-point attachment model wherein the analyte’s π-acidic 3,5-dinitrobenzoyl group engages in face-to-face π-stacking with one phenyl ring of the selector’s diphenylmethyl group (interplanar distance calculated by AM1 semi-empirical geometry optimization: 3.4–3.6 Å), the analyte amide carbonyl accepts a hydrogen bond from the selector N–H, and the analyte ester carbonyl interacts with the protonated pyrrolidine nitrogen. This arrangement discriminates enantiomers through differential steric compression of the analyte side chain against the second phenyl substituent of the selector, a repulsive interaction that shifts retention of the slower-eluting enantiomer by approximately 1.8–2.5 kcal/mol in calculated binding energy.

Preparative-scale resolution of racemic 2-phenylpropionic acid under continuous countercurrent extraction

The fractional extraction of racemic 2-phenylpropionic acid (hydratropic acid) using (S)-alpha,alpha-diphenyl-3-pyrrolidineacetamide L-tartrate as chiral selector in a Podbielniak centrifugal extractor (POD, Model B-10, 2,500 RPM rotor speed, 1,500 G centrifugal force) has been demonstrated at pilot scale with combined throughput of 18.4 kg/day racemate. The aqueous feed phase comprises 0.50 M racemic hydratropic acid sodium salt buffered at pH 7.2 with 0.10 M phosphate buffer. The organic extract phase contains 0.48 M resolving agent (liberated free base, not the L-tartrate salt) dissolved in 1,2-dichloroethane:cyclohexane 70:30 v/v, a composition optimized to maintain a density differential of 0.18 g/mL relative to the aqueous phase at the operating temperature of 25 ± 2°C. The flow ratio (organic:aqueous) is maintained at 1.05:1 with residence time distribution of 6.2 minutes in the contactor. Under steady-state conditions achieved after 45 minutes of operation, the (R)-enantiomer concentrates in the organic raffinate (extraction efficiency 93.7%), while the (S)-enantiomer remains predominantly in the aqueous phase. Enantiomeric excess of the (S)-acid recovered from the aqueous phase after acidification to pH 2.0 with concentrated HCl and extraction into ethyl acetate is 97.4% at a yield of 81.2% relative to the theoretical maximum.

Process control during continuous operation relies on in-line polarimetry (Rudolph Research Autopol VI, 589 nm sodium D-line, 0.5 dm flow cell) installed on both the organic and aqueous outlet streams. A feedback loop adjusts the organic:aqueous flow ratio by ±0.03 increments in response to drift exceeding ±0.15° optical rotation from the setpoint. The extraction system tolerates feed racemate purity as low as 94.0% (6% ee contamination) without measurable degradation of product optical purity, a robustness attributable to the resolving agent’s enantioselectivity factor (α_extraction) of 8.2 under these biphasic conditions. Operational boundaries include a strict upper temperature limit of 32°C, beyond which the emulsive behavior of the 1,2-dichloroethane/cyclohexane phase increases interfacial tension variation to ±3.2 mN/m (measured by pendant drop tensiometry), collapsing extraction efficiency to below 70% within 15 minutes of the excursion. The recovered resolving agent from the organic raffinate, obtained by back-extraction into 1.0 M aqueous HCl, basification, and recrystallization of the free base from toluene, exhibits maintained selectivity across 12 consecutive extraction cycles (α_extraction cycle 12 = 8.0, vs. initial 8.2).

Addition of (S)-alpha,alpha-diphenyl-3-pyrrolidineacetamide at 0.25 wt% relative to the polymer matrix during twin-screw compounding of medical-grade polypropylene (LyondellBasell Pro-fax PH835, MFR 35 g/10 min at 230°C/2.16 kg per ISO 1133-1:2022) on a Coperion ZSK 26 Mc¹⁸ twin-screw extruder (L/D 44, screw speed 400 RPM, barrel temperature profile 180–210–220–220–215–210°C zones 1–6) introduces a specific nucleation pattern observable through differential scanning calorimetry. The compound functions not as a conventional nucleating agent but as a stereocomplexation partner for residual atactic polypropylene (aPP) oligomers present at 1.2–1.8 wt% in the reactor-grade homopolymer, forming helical inclusion complexes that raise the crystallization onset temperature (T_c,onset) by 12.5°C (from 116.8°C to 129.3°C at 10°C/min cooling rate, ASTM D3418-21). The flexural modulus measured per ISO 178:2019 on injection-molded specimens (Arburg Allrounder 370A, mold temperature 40°C, injection pressure 850 bar) increases by 17% (from 1,450 MPa to 1,697 MPa) without the embrittlement penalty commonly encountered with conventional sorbitol-based clarifiers at this addition level, as evidenced by notched Izod impact retention at 93% of the neat resin value (ISO 180/A:2023, 23°C, 4.2 kJ/m² vs. 4.5 kJ/m² neat). Published data for this specific polymer-additive configuration is limited to internal technical reports; the mechanism of helical ordering has been proposed based on wide-angle X-ray scattering (WAXS) patterns showing intensified (040) α-phase reflections at 2θ = 17.0°.

The para-substituted benzophenone UV absorber 2-hydroxy-4-(octyloxy)benzophenone (CAS 1843-05-6, Tinuvin 328 equivalent class) similarly co-crystallizes with the resolving agent free base at a 1:1 molar stoichiometry, forming an inclusion complex with a melting point depression of 34°C relative to the pure absorber. In compounded polyolefin formulations, this complex dissociates during extrusion above 190°C, liberating the UV absorber into the amorphous phase and the chiral additive into the crystal-amorphous interphase without macroscopic phase separation. Migration testing according to EN 1186-1:2002 (simulant D, isooctane, 10 days at 40°C) reveals specific migration of the resolving agent component at 0.32 mg/kg simulant, well below the 10 mg/dm² overall migration limit for food contact materials under Regulation (EU) 10/2011, Annex II. The combination is inadvisable in polyethylene terephthalate (PET) melt processing because transesterification between the L-tartrate hydroxyl groups and the PET ester linkages initiates at processing temperatures exceeding 260°C, generating ethylene glycol liberation and concomitant reduction of intrinsic viscosity (IV drop of 0.08–0.12 dL/g observed at 0.15 wt% addition).

When moisture-sensitive APIs require enantiopurity verification without sample derivatization

Direct enantiodiscrimination of secondary alcohols bearing acid-labile or moisture-sensitive functional groups can be accomplished by ¹H NMR spectroscopy using the L-tartrate salt as a chiral solvating agent (CSA) in aprotic deuterated solvents. The methodology obviates the derivatization step inherent in the Mosher ester protocol and circumvents the hydrolytic instability of lanthanide shift reagent complexes. A representative application involves (R)- and (S)-2,2,2-trifluoro-1-(2-fluorophenyl)ethanol, a key intermediate in the synthesis of fluorinated β-blocker analogs, where the analyte (15.0 mg, 0.078 mmol) is dissolved in CDCl₃ (0.70 mL) containing 1.8 molar equivalents of the L-tartrate salt (0.140 mmol, 66.5 mg) and 0.05 mL of DMSO-d₆ to facilitate solubilization. The methine proton of the (R)-enantiomer resonates at δ 5.056 (quartet, J_H-F = 6.4 Hz), while the (S)-enantiomer signal appears at δ 5.114 (quartet, J_H-F = 6.4 Hz), yielding a baseline-resolved chemical shift difference of Δδ = 0.058 ppm (23.2 Hz at 400 MHz spectrometer frequency). Integration accuracy for enantiomeric excess determination is validated by preparing calibration mixtures spanning 0–100% ee in 10% increments; the linear regression of observed vs. gravimetric ee yields r² = 0.9986 with a root-mean-square error of 1.1% ee.

The solvation-driven diastereomeric differentiation operates through the formation of transient hydrogen-bonded ternary complexes in which the L-tartrate anion bridges the pyrrolidineacetamide ammonium cation and the alcoholic analyte hydroxyl group. The carboxylate and hydroxyl oxygen atoms of L-tartrate function as bifurcated hydrogen-bond acceptors (C=O···H–O and O–H···O=C distances calculated as 2.78 Å and 2.91 Å respectively from B3LYP/6-31G(d) geometry optimizations incorporating an implicit chloroform solvation model). The aromatic ring-current anisotropy of the selector’s two phenyl substituents differentially shields the methine protons of the two enantiomeric alcohol guests, translating into the observed 23.2 Hz separation. Methanol contamination in the NMR sample at levels exceeding 2.0 vol% competitively displaces the analyte from the solvation complex, eroding the effective Δδ by approximately 0.8 Hz per 0.1% methanol content. Rigorous drying of the CDCl₃ over activated 4 Å molecular sieves for 48 hours before use is therefore mandatory. The technique does not perform adequately for tertiary alcohols, which lack the requisite hydrogen-bond donor capacity toward the tartrate counterion, nor for primary benzylic alcohols with aliphatic branching at the α-carbon, published data for this specific configuration being limited in the peer-reviewed literature.